FDA approves Besremi for essential thrombocythemia, first new ET drug in nearly 30 years

The US FDA approved Besremi (ropeginterferon alfa-2b-njft) for essential thrombocythemia (ET), the first new FDA-approved ET drug in nearly 30 years, based on superior efficacy compared to anagrelide in the Phase III SURPASS-ET trial.

This Wire brief sits within Fusion42's coverage of Biotech.